Modulation of prekallikrein (PKK) expression
AssigneeIonis Pharmaceuticals, Inc.
InventorsSusan M. Freier, Huynh-Hoa Bui
Life of this patent
Estimating the term…
Abstract
Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.
Claims19
A compound, comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and comprising a nucleobase sequence comprising at least 12 consecutive nucleobases complementary to an equal length portion of nucleobases 30570-30610 or 33183-33242 of SEQ ID NO:
- 10, wherein the modified oligonucleotide comprises:
- a gap segment consisting of linked deoxynucleosides;
- a 5′ wing segment consisting of linked nucleosides;
- a 3′ wing segment consisting of linked nucleosides;
- wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.
A compound consisting of a modified oligonucleotide according to the following formula:
- mCes mCes mCes mCes mCes Tds Tds mCds Tds Tds Tds Ads Tds Ads Gds mCes mCes Aes Ges mCe;
- wherein,
- A=an adenine,
- mC=a 5′-methylcytosine;
- G=a guanine,
- T=a thymine,
- e=a 2′-O-methoxyethyl modified nucleoside,
- d=a 2′-deoxynucleoside, and
- s=a phosphorothioate internucleoside linkage.
A compound consisting of a modified oligonucleotide according to the following formula:
Dependencies are inferred from the claim text.